Century Therapeutics Q2 GAAP EPS misses estimates by $0.05

Seeking Alpha··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Century Therapeutics reported second-quarter 2026 GAAP earnings per share of negative $0.17, missing analyst estimates by $0.05. The company also announced a cash runway extending into the first quarter of 2029, supported by cash, cash equivalents, and investments totaling $197.2 million as of June 30, 2026.

Impact on assets 1

Biotech & Genomic Medicine▼